Welcome to the our Aesthetic Medicine news roundup, 21 May 2021.

News Roundup

Australian Breast Device Registry helps with Victorian patient safety
As of today, the Australian Breast Device Registry (ABDR) will be at the forefront to help the Victorian public become better informed about a rare form of cancer linked to breast implants.

AbbVie Inc. (NYSE: ABBV) Topped Its Sales Forecast For Botox And Other Cosmetic Products In Q1
AbbVie Inc. (NYSE: ABBV) said that it expects cosmetics treatments like Botox’s demand in Brazil and Europe to recover in the second half of this year as nations easy restriction and measures put in place to curb the spread of COVID-19.

Management of Tear Trough with Hyaluronic Acid Fillers: A Clinical-Practice Dual Approach
Tear trough deformity (TTD) is currently a major concern for many individuals that seek periorbital rejuvenation. Among the different options currently available for treating TTD, hyaluronic acid (HA) filler injections have become increasingly popular.

The new rush on cosmetic and plastic surgery treatments before the comeback of face-to-face meetings
“Thanks to vaccines, normal life is starting to return for many. Some of our surgeons have reported they are seeing higher demand than even pre-pandemic,” says Dr. Alan Matarasso, past president of the American Society of Plastic Surgeons.

Cosmetic medicine expert says NZ due for regulation after UK bans Botox and fillers for under 18s
Dr Catherine Stone, who has 20 years of experience in non-surgical cosmedicine, discusses the Therapeutic Medicines Bill.

Is luxury aesthetic medicine beauty’s next boom in China?
Chinese demand, particularly among Gen Z, is growing fast for medical aesthetic treatments and products. This could be just the beginning.


Previous articleAustralian ‘Super Stool’ For Chronic Gut Disease
Next articleSpectra XT: The Extended Platform